Radiopharm Theranostics Limited (ASX:RAD)

Market Cap	66.22M
Revenue (ttm)	13.54M
Net Income (ttm)	-36.70M
Shares Out	2.36B
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	977,963
Average Volume	4,960,273
Open	0.0280
Previous Close	0.0270
Day's Range	0.0270 - 0.0280
52-Week Range	0.0190 - 0.0420
Beta	0.81
RSI	59.45
Earnings Date	Aug 29, 2025

About Radiopharm Theranostics

Radiopharm Theranostics Limited engages in the research and development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical needs. It develops RAD 204, a programmed death-ligand 1 (PD-L1) for the treatment of non-small cell lung cancer (NSCLC); RAD 202, a human epidermal growth factor receptor 2 (HER2) to treat breast cancer and other solid tumors; and RAD 301, a diagnostic radiopharmaceutical targeting αvβ6 integrin in pancreatic ductal adenocarcinoma patients. The company also develops RAD 302, a...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2021
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAD

Financial Performance

In 2025, Radiopharm Theranostics's revenue was 13.54 million, an increase of 591.26% compared to the previous year's 1.96 million. Losses were -36.70 million, -23.45% less than in 2024.